369 related articles for article (PubMed ID: 27989797)
1. Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats.
Sawada K; Wu-Wong JR; Chen YW; Wessale JL; Kanai G; Kakuta T; Fukagawa M
J Steroid Biochem Mol Biol; 2017 Mar; 167():48-54. PubMed ID: 27989797
[TBL] [Abstract][Full Text] [Related]
2. Cardiac effect of vitamin D receptor modulators in uremic rats.
Mizobuchi M; Ogata H; Yamazaki-Nakazawa A; Hosaka N; Kondo F; Koiwa F; Kinugasa E; Shibata T
J Steroid Biochem Mol Biol; 2016 Oct; 163():20-7. PubMed ID: 27072785
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.
Wu-Wong JR; Chen YW; Wessale JL
Am J Physiol Renal Physiol; 2015 Feb; 308(4):F309-19. PubMed ID: 25503724
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects.
Chen B; Kawai M; Wu-Wong JR
Bioorg Med Chem Lett; 2013 Nov; 23(21):5949-52. PubMed ID: 24035340
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease.
Fujii H; Yonekura Y; Nakai K; Kono K; Goto S; Nishi S
J Steroid Biochem Mol Biol; 2017 Mar; 167():55-60. PubMed ID: 27818277
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
Noonan W; Koch K; Nakane M; Ma J; Dixon D; Bolin A; Reinhart G
Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
[TBL] [Abstract][Full Text] [Related]
7. Two novel vitamin D receptor modulators with similar structures exhibit different hypercalcemic effects in 5/6 nephrectomized uremic rats.
Wu-Wong JR; Kawai M; Chen YW; Wessale JL; Huang CJ; Wu MT; Nakane M
Am J Nephrol; 2013; 37(4):310-9. PubMed ID: 23548814
[TBL] [Abstract][Full Text] [Related]
8. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content.
Takahashi F; Finch JL; Denda M; Dusso AS; Brown AJ; Slatopolsky E
Am J Kidney Dis; 1997 Jul; 30(1):105-12. PubMed ID: 9214408
[TBL] [Abstract][Full Text] [Related]
9. Persistent downregulation of calcium-sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation.
Lewin E; Garfia B; Recio FL; Rodriguez M; Olgaard K
J Am Soc Nephrol; 2002 Aug; 13(8):2110-6. PubMed ID: 12138143
[TBL] [Abstract][Full Text] [Related]
10. Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats.
Mendoza FJ; Lopez I; Canalejo R; Almaden Y; Martin D; Aguilera-Tejero E; Rodriguez M
Am J Physiol Renal Physiol; 2009 Mar; 296(3):F605-13. PubMed ID: 19091789
[TBL] [Abstract][Full Text] [Related]
11. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
Slatopolsky E; Finch J; Ritter C; Takahashi F
Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S40-7. PubMed ID: 9808142
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Brancaccio D; Bommer J; Coyne D
Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
[TBL] [Abstract][Full Text] [Related]
13. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
14. Local NF-κB Activation Promotes Parathyroid Hormone Synthesis and Secretion in Uremic Patients.
Mao J; Wang M; Ni L; Gong W; Jiang X; Zhang Q; Zhang M; Wen D; Chen J
Endocrinology; 2021 Jul; 162(7):. PubMed ID: 33912936
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis.
Wu-Wong JR; Nakane M; Gagne GD; Brooks KA; Noonan WT
Int J Endocrinol; 2010; 2010():621687. PubMed ID: 20204178
[TBL] [Abstract][Full Text] [Related]
16. The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands.
Brown AJ; Zhong M; Finch J; Ritter C; Slatopolsky E
Endocrinology; 1995 Apr; 136(4):1419-25. PubMed ID: 7895652
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats.
Shiizaki K; Negi S; Hatamura I; Sakaguchi T; Saji F; Kunimoto K; Mizobuchi M; Imazeki I; Ooshima A; Akizawa T
J Am Soc Nephrol; 2005 Jan; 16(1):97-108. PubMed ID: 15574509
[TBL] [Abstract][Full Text] [Related]
18. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
[TBL] [Abstract][Full Text] [Related]
19. Regulation of intestinal vitamin D receptor expression in experimental uraemia: effects of parathyroidectomy and administration of PTH.
Szabó A; Schmutz A; Pesian S; Schmidt-Gayk H; Ritz E; Reichel H
Nephrol Dial Transplant; 1998 Feb; 13(2):340-9. PubMed ID: 9509444
[TBL] [Abstract][Full Text] [Related]
20. Mapping the time-dependent effects of paricalcitol on serum calcium, phosphorus and parathyroid hormone levels in 5/6 nephrectomized uremic rats.
Wu-Wong JR; Nakane M; Chen YW
Life Sci; 2013 Feb; 92(2):161-6. PubMed ID: 23261531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
